About Us | Contact Us |        

Novel Personalized Management Approaches in Rheumatoid Arthritis

Tailoring Approaches to Management in Patients with RA: What’s New?
0.5 AMA PRA Category 1 Credit(s)
Launch Date:
May 16, 2017
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:


Relevant Terms:

Rheumatoid Arthritis

Vibeke Strand, MD, MACR, FACP

Vibeke Strand, MD, MACR, FACP
Adjunct Clinical Professor
Division of Immunology/Rheumatology
Stanford University School of Medicine
Stanford, CA

Vibeke Strand, MD, MACR, FACP, is an adjunct clinical professor in the division of immunology and rheumatology at Stanford University School of Medicine. She serves as a consultant in clinical research and regulatory affairs to pharmaceutical and biotech companies. She graduated from Swarthmore College with honors, and she attended the University of California San Francisco School of Medicine, where she also completed her subspecialty fellowship in rheumatology. She was 1 of 8 in the first primary care internal medicine residency at Michigan State University. 
Dr Strand has been a clinical rheumatologist for more than 35 years. Her professional interests include development of outcome measures methodology and clinical and regulatory strategies leading to approval of new agents for treatment of autoimmune diseases. Since 1991, Dr Strand has led a consulting practice offering clinical research and regulatory expertise. 
Dr Strand has authored more than 230 original publications and reviews, as well as 50 chapters, and has co-edited several books and multiple proceedings. She is a Fellow of the American College of Physicians, a Master of the American College of Rheumatology, serves on the editorial board of multiple journals, and is a member of the Cosmos Club.

Martin Jan Bergman, MD, FACR, FACP, FCPP

Martin Jan Bergman, MD, FACR, FACP, FCPP
Clinical Associate Professor of Medicine
Drexel University School of Medicine
Philadelphia, PA

Martin Jan Bergman, MD, FACR, FACP, FCPP, is clinical associate professor of medicine at the Drexel University School of Medicine in Philadelphia, and chief of the division of rheumatology at Taylor Hospital in Ridley Park, Pennsylvania. He is also a full-time clinical rheumatologist in a private practice setting, with over 25 years of clinical experience.

In addition to issues affecting the running of a successful clinical practice, Dr Bergman is interested in issues facing practicing rheumatologists on a daily basis. With collaborators, Dr Bergman has played a pivotal role in the development of patient management tools, particularly the RAPID 3. This disease measurement tool is now an outcomes measure accepted by the American College of Rheumatology and used worldwide.

Dr Bergman is a recognized leader in the field of clinical and patient reported outcomes, and has spoken both nationally and internationally on this and other topics. For his work, he has received the Joseph L Hollander Award for Excellence and Achievement in Rheumatology by the Southeast Pennsylvania Arthritis Foundation and has been elected as a Fellow of the College of Physicians of Philadelphia. 

Eric M. Ruderman, MD

Eric M. Ruderman, MD
Professor of Medicine, Department of Rheumatology
Northwestern University
Chicago, IL

Eric M. Ruderman, MD, is a professor of medicine and clinical practice director of the rheumatology clinic at Northwestern University. His primary responsibilities include patient care, fellowship teaching, clinical administration, and management of clinical trials in rheumatoid arthritis and other forms of inflammatory arthritis. He also co-directs a cooperative clinic for the management of psoriasis and psoriatic arthritis.

Dr Ruderman received his undergraduate degree in English literature from Princeton University and his medical degree from the Albert Einstein College of Medicine. After a residency in internal medicine at the Hospital of the University of Pennsylvania, he completed a rheumatology fellowship at Brigham and Women's Hospital, with a concurrent research fellowship at the Harvard School of Public Health. 
Dr Ruderman has served as principal investigator on over 50 clinical trials, and he is involved in several projects that link clinical practice and the research agenda in the rheumatology clinic. In addition to his research efforts, he serves as a vice chair of Northwestern University's institutional review board. He is the immediate past chair of the Communications and Marketing Committee of the American College of Rheumatology and a co-editor of their Hotline newsletter. Dr Ruderman is the associate editor for the rheumatoid arthritis section of Journal of Rheumatology.
1. Utilize appropriate risk-assessment and monitoring tools for RA patients to assess disease activity and direct individualized management decisions
2. Integrate new and emerging IL-6 directed therapies in rheumatoid arthritis for individualized treatment plans based on safety and efficacy data, patient selection data, and the rationale for targeting the IL-6 pathway
3. Incorporate strategies for a collaborative approach to RA care that includes a multidisciplinary team of health professionals and includes patient preferences into treatment selection

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and RMEI Medical Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Joint Providership Statement
This CME activity is jointly provided by the University of Cincinnati and RMEI Medical Education, LLC.
This activity is supported by independent educational grants from Genzyme, a Sanofi Company and Regeneron Pharmaceuticals.   
According to the disclosure policy of the University of Cincinnati College of Medicine, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. Disclosure will be made at the time of activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Vibeke Strand, MD, MACR, FACP, has affiliations with AbbVie, Alder, Amgen Inc., Anthera, Asana, AstraZeneca, aTyr, Bayer, Biogen ldec, Boehringer Ingelheim, BMS, Carbylan, Celgene, Celltrion, CORRONA, Crescendo/Myriad Genetics, EMD Serono, Eupraxia, Genentech/Roche, GlaxoSmithKline, Horizon, Iroko, Janssen, Jazz Pharmaceuticals, Kezar, Kypha, Lilly, Merck, Novartis, Pfizer, Protagen, Regeneron, Samsung, Samumed, Sandoz, SKK, UCB, and XTL (Consulting Fees); and AbbVie, Amgen, Anthera, AstraZeneca, Bayer, Biogen ldec, BMS, Carbylan, Celltrion, Crescendo, EMD Serono, Genentech/Roche, GSK, Horizon, Iroko, Janssen, Jazz, Lilly, Merck, Novartis, Pfizer, Protagen, Regeneron, Samsung, Sandoz, Sanofi, and UCB (Advisory Boards)
  • Martin Jan Bergman, MD, FACR, FACP, FCPP, has affiliations with AbbVie, Amgen, Celgene, Genentech, Janssen, Novartis, and Pfizer (Advisory Boards); Johnson & Johnson and Pfizer (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Their Agents); AbbVie and Celgene (Speaker’s Bureau); and Spouse: Amgen (Consulting Fees)
  • Eric M. Ruderman, MD, has affiliations with BMS, Lilly (Advisory Boards); AbbVie, Amgen, Genentech/Roche, GSK, Lilly, Novartis, Pfizer, and Vertex (Consulting Fees); and Pfizer (Contracted Research/Grants).
University of Cincinnati
  • Susan P. Tyler, MEd, CMP, CHCP, CME Director, has no affiliations with commercial interests relative to the content to disclose.
  • Rick E. Ricer, MD, Professor Emeritus, CME Physician Reviewer, has no affiliations with commercial interests relative to the content to disclose.
  • Deborah Cole, BS, Program Coordinator, has no affiliations with commercial interests relative to the content to disclose.
RMEI Medical Education, LLC
  • Sy Schlager, MD, PhD, has no affiliations with commercial interests relative to the content to disclose. 
  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests relative to the content to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests relative to the content to disclose.
  • Leslie Treff, JD, has no affiliations with commercial interests relative to the content to disclose.
The opinions expressed during the enduring activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.
Faculty members are required to inform the audience when they are discussing off label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.
Estimated time to complete: 0.5 hours
Medium: Internet
There is no fee for this educational activity.
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to .5 AMA PRA Category 1 Credits™. A statement of credit will be available to print from your user history page. Users must:
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test and evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. You must score 70% or higher on the post-test to receive credit for this activity. Participants have 3 attempts to successfully pass the post-test. 
Accreditation Support:
Please contact the University of Cincinnati Continuing Medical Education Department at uccme@uc.edu or call 513-558-7277.

Technical Support:
For any technical issues or issues with your CME Certificate, please visit: http://www.realcme.com/cms/support-center
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.